The Authors Reply: Reply on "Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients".
作者信息
Kim Su Jin, Shin In-Soo, Eun Sung-Jong, Whangbo Taeg-Keun, Kim Jin Wook, Cho Young Sam, Kim Joon Chul
机构信息
Department of Urology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
Department of Education, Jeonju University, Jeonju, Korea.
出版信息
Int Neurourol J. 2017 Sep;21(3):231-232. doi: 10.5213/inj.1734986.493. Epub 2017 Sep 12.
Abstract
摘要
相似文献
1
The Authors Reply: Reply on "Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients".作者回复：对“证据足够吗？：坦索罗辛0.2毫克和坦索罗辛0.4毫克作为亚洲良性前列腺增生患者初始治疗剂量疗效的系统评价和网络荟萃分析”的回复。
Int Neurourol J. 2017 Sep;21(3):231-232. doi: 10.5213/inj.1734986.493. Epub 2017 Sep 12.
2
Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients.证据是否足够？：坦索罗辛0.2毫克和坦索罗辛0.4毫克作为亚洲良性前列腺增生患者初始治疗剂量疗效的系统评价和网状Meta分析
Int Neurourol J. 2017 Mar 24;21(1):29-37. doi: 10.5213/inj.1734826.413.
3
Letter to the Editor: Commentary on "Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients".致编辑的信：关于“证据足够了吗？：坦索罗辛0.2毫克和坦索罗辛0.4毫克作为亚洲良性前列腺增生患者初始治疗剂量疗效的系统评价和网络荟萃分析”的评论
Int Neurourol J. 2017 Sep;21(3):229-230. doi: 10.5213/inj.1734962.481. Epub 2017 Sep 12.
4
General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia: a systematic review and meta-analysis.低剂量坦索罗辛（0.2毫克）作为良性前列腺增生相关下尿路症状一线治疗的总体效果：一项系统评价和荟萃分析
Curr Med Res Opin. 2015 Feb;31(2):353-65. doi: 10.1185/03007995.2014.980887. Epub 2014 Nov 7.
5
Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia.坦索罗辛联合度他雄胺与坦索罗辛单药治疗良性前列腺增生的疗效和安全性的荟萃分析。
BMC Urol. 2019 Mar 11;19(1):17. doi: 10.1186/s12894-019-0446-8.
6
Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction.坦索罗辛联合他达拉非对比他达拉非单药治疗前列腺增生伴勃起功能障碍的疗效和安全性的 Meta 分析。
Am J Mens Health. 2019 Sep-Oct;13(5):1557988319882597. doi: 10.1177/1557988319882597.
7
Effectiveness of the addition of tadalafil to tamsulosin in the treatment of acute urinary retention in patients with benign prostatic hyperplasia: A randomized clinical trial.他达拉非联合坦索罗辛治疗良性前列腺增生患者急性尿潴留的有效性：一项随机临床试验。
Urologia. 2018 May;85(2):51-54. doi: 10.1177/0391560317749427. Epub 2018 Mar 26.
8
Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia.
Med Arch. 2012;66(3):173-6. doi: 10.5455/medarh.2012.66.173-176.
9
Beneficial Effect of Increasing the Dose of Tamsulosin to 0.4 mg in Japanese Patients with Benign Prostatic Hyperplasia.增加坦索罗辛剂量至0.4毫克对日本良性前列腺增生患者的有益作用。
J Rural Med. 2011;6(2):60-4. doi: 10.2185/jrm.6.60. Epub 2011 Dec 7.
10
Tamsulosin for the treatment of benign prostatic hypertrophy.坦索罗辛用于治疗良性前列腺增生。
Ann Pharmacother. 2000 Feb;34(2):188-99. doi: 10.1345/aph.18263.
本文引用的文献
1
Letter to the Editor: Commentary on "Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients".致编辑的信：关于“证据足够了吗？：坦索罗辛0.2毫克和坦索罗辛0.4毫克作为亚洲良性前列腺增生患者初始治疗剂量疗效的系统评价和网络荟萃分析”的评论
Int Neurourol J. 2017 Sep;21(3):229-230. doi: 10.5213/inj.1734962.481. Epub 2017 Sep 12.
2
Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients.证据是否足够？：坦索罗辛0.2毫克和坦索罗辛0.4毫克作为亚洲良性前列腺增生患者初始治疗剂量疗效的系统评价和网状Meta分析
Int Neurourol J. 2017 Mar 24;21(1):29-37. doi: 10.5213/inj.1734826.413.
3
Assessment of Tamsulosin 0.2 mg for Symptomatic Bladder Outlet Obstruction Secondary to Benign Prostatic Enlargement: Data from a Korean Multicenter Cross-Sectional Study.
Urol Int. 2015;95(1):50-5. doi: 10.1159/000366007. Epub 2015 Apr 22.
Zotero 插件